Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020
06 Mai 2020 - 3:15PM
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced it will report its first quarter 2020
financial and operating results following the close of U.S.
financial markets on Monday, May 11, 2020.
|
|
Conference call details are as follows: |
|
|
Date: |
May 11, 2020 |
Time: |
4:30 p.m. U.S. Eastern Time (ET) |
Dial-in number: |
(877) 212-6076 (Domestic) or (707) 287-9331
(International) |
Passcode: |
1274143 |
Webcast: |
www.novavax.com, “Investors” / “Events” |
|
Conference call and webcast replay: |
|
|
Dates: |
Starting at 7:30 p.m. ET, May 11, 2020 until |
|
7:30 p.m. ET May 18, 2020 |
Dial-in number: |
(855) 859-2056 (Domestic) or (404) 537-3406
(International) |
Passcode: |
1274143 |
Webcast: |
www.novavax.com, “Investors” / “Events”, until August 11,
2020 |
|
|
About Novavax
Novavax, Inc. (Nasdaq:NVAX), is a late-stage
biotechnology company that promotes improved health globally
through the discovery, development, and commercialization of
innovative vaccines to prevent serious infectious diseases and
address urgent, global health needs. Novavax recently initiated
development of NVX-CoV2373, its vaccine candidate against
SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical
trial results expected in July of 2020. NanoFlu™, its quadrivalent
influenza nanoparticle vaccine, met all primary objectives in its
pivotal Phase 3 clinical trial in older adults. Both vaccine
candidates incorporate Novavax’ proprietary saponin-based Matrix-M™
adjuvant in order to enhance the immune response and stimulate high
levels of neutralizing antibodies. Novavax is a leading innovator
of recombinant vaccines; its proprietary recombinant technology
platform combines the power and speed of genetic engineering to
efficiently produce highly immunogenic nanoparticles in order to
address urgent global health needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contacts:
InvestorsErika Trahanir@novavax.com240-268-2022
Westwicke John
Woolfordjohn.woolford@westwicke.com443-213-0506
MediaAmy Speakamy@speaklifescience.com617-420-2461
Novavax (NASDAQ:NVAX)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
Von Apr 2023 bis Apr 2024